About nyxoah sa - NYXH
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
NYXH At a Glance
Nyxoah SA
Rue Edouard Belin 12
Mont-Saint-Guibert, Walloon Region 1435
| Phone | 32-10-22-23-55 | Revenue | 11.31M | |
| Industry | Medical Specialties | Net Income | -101,667,944.68 | |
| Sector | Health Technology | 2025 Sales Growth | 131.239% | |
| Fiscal Year-end | 12 / 2026 | Employees | 154 | |
| View SEC Filings |
NYXH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.168 |
| Price to Book Ratio | 3.578 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.941 |
| Enterprise Value to Sales | 15.552 |
| Total Debt to Enterprise Value | 0.281 |
NYXH Efficiency
| Revenue/Employee | 73,910.791 |
| Income Per Employee | -664,496.37 |
| Receivables Turnover | 1.27 |
| Total Asset Turnover | 0.075 |
NYXH Liquidity
| Current Ratio | 1.237 |
| Quick Ratio | 1.142 |
| Cash Ratio | 0.98 |
NYXH Profitability
| Gross Margin | 18.383 |
| Operating Margin | -845.898 |
| Pretax Margin | -888.982 |
| Net Margin | -899.052 |
| Return on Assets | -67.07 |
| Return on Equity | -115.967 |
| Return on Total Capital | -94.914 |
| Return on Invested Capital | -92.897 |
NYXH Capital Structure
| Total Debt to Total Equity | 85.644 |
| Total Debt to Total Capital | 46.133 |
| Total Debt to Total Assets | 35.516 |
| Long-Term Debt to Equity | 37.263 |
| Long-Term Debt to Total Capital | 20.072 |